MedTrace Logo

A 28 Day Parallel Group Study to Assess the Effects of RDN-929

NCT03963973 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2020-02-20

No results posted yet for this study

Summary

Eligibility will be assessed during a screening period of up to 4 weeks. Subjects will take study medication once daily up to and including Day 28. Safety, tolerability and PK will be measured at each visit.

Conditions

  • Healthy

Interventions

DRUG

RDN-929 oral capsule

low, medium and high dose

DRUG

Placebo oral capsule

matching placebo dose

Sponsors & Collaborators

  • Alkermes, Inc.

    lead INDUSTRY

Principal Investigators

  • PI · QPS Holdings LLC

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-16
Primary Completion
2020-01-22
Completion
2020-01-22

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03963973 on ClinicalTrials.gov